User login
CHICAGO – The oral drug duo of sofosbuvir and ribavirin produced good cure rates in a study of 419 patients with hepatitis C genotype 2 or 3.
Dr. Bruce R. Bacon, who was not involved in the study, highlighted the regimen’s efficacy even in patients with cirrhosis or who had failed previous therapy. Hear his perspective on treating genotypes 2 and 3 in this interview at the annual Digestive Disease Week.
Dr. Bacon is the James F. King Endowed Chair in Gastroenterology and a professor of medicine at Saint Louis University.
He reported financial associations with Gilead Sciences, which funded the study, and with AbbVie and Janssen Pharmaceuticals.
On Twitter @sherryboschert
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
CHICAGO – The oral drug duo of sofosbuvir and ribavirin produced good cure rates in a study of 419 patients with hepatitis C genotype 2 or 3.
Dr. Bruce R. Bacon, who was not involved in the study, highlighted the regimen’s efficacy even in patients with cirrhosis or who had failed previous therapy. Hear his perspective on treating genotypes 2 and 3 in this interview at the annual Digestive Disease Week.
Dr. Bacon is the James F. King Endowed Chair in Gastroenterology and a professor of medicine at Saint Louis University.
He reported financial associations with Gilead Sciences, which funded the study, and with AbbVie and Janssen Pharmaceuticals.
On Twitter @sherryboschert
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
CHICAGO – The oral drug duo of sofosbuvir and ribavirin produced good cure rates in a study of 419 patients with hepatitis C genotype 2 or 3.
Dr. Bruce R. Bacon, who was not involved in the study, highlighted the regimen’s efficacy even in patients with cirrhosis or who had failed previous therapy. Hear his perspective on treating genotypes 2 and 3 in this interview at the annual Digestive Disease Week.
Dr. Bacon is the James F. King Endowed Chair in Gastroenterology and a professor of medicine at Saint Louis University.
He reported financial associations with Gilead Sciences, which funded the study, and with AbbVie and Janssen Pharmaceuticals.
On Twitter @sherryboschert
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
AT DDW 2014
